news.abbvie.comAbbVie News Center - News

Investors News Center Patient Assistance News Center Menu News Media Resources Fact Sheets Images Video Media Contacts Investors News Center Patient Assistance Home / News News Latest news Get News Alerts by Email May 13, 2024 AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders - Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders NORTH... May 06, 2024 AbbVie to Present at the Bank of America Securities Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024. Robert A. Michael, president and chief operating officer, Scott T. Reents,... April 30, 2024 AbbVie Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany New state-of-the-art research and development (R&D) facility at Ludwigshafen to expand discovery and development of new medicines across core therapeutic areas Investment reinforces the importance... More » AbbVie on Twitter Looking for more news from AbbVie? Follow us on social media . Press Kits Our press kits are designed to provide journalists with a broad range of background information on our company. more Image library Our media library provides you with our official AbbVie media including our logo, building and leaders. more Subscribe Stay up to date on recent news, articles, and more. more standard https://news.abbvie.com/index.php?s=20300News Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Get News Alerts by Email Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Category All Categories News Type - Corporate News - Product News - R&D News - Responsibility News - Media Statements - News Briefs Therapeutic Area - Allergan Aesthetics - Eye Care - General Medicine - Immunology - Neuroscience - Oncology - Virology - Women’s Health Uncategorized Keywords Go Advanced Search Search Search Headlines Only Category All Categories News Type - Corporate News - Product News - R&D News - Responsibility News - Media Statements - News Briefs Therapeutic Area - Allergan Aesthetics - Eye Care - General Medicine - Immunology - Neuroscience - Oncology - Virology - Women’s Health Uncategorized From To Asset Types Video Audio Photos Documents Events Standard Basic Search May 13, 2024 AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders May 06, 2024 AbbVie to Present at the Bank of America Securities Healthcare Conference April 30, 2024 AbbVie Reinforces Commitment to Science and Innovation with a €150 million Euro Investment in New Cutting-Edge Research and Development Facility in Germany April 26, 2024 AbbVie Reports First-Quarter 2024 Financial Results April 25, 2024 New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study April 23, 2024 Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands Video 1 April 18, 2024 Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis April 12, 2024 AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine April 09, 2024 SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne April 04, 2024 AbbVie to Host First-Quarter 2024 Earnings Conference Call Show 5 10 25 50 100 per page « 1 2 3 4 5 6 7 8 9 … 203 » Our history Explore where we’ve been and how we continue to go beyond medicine to make a remarkable impact. Learn more Societal impact Our commitment to science is a commitment to better our society. Read our 2022 ESG report Ratings and recognition We’ve been honored to receive some of the most prestigious ratings and recognnitions in the industry. Learn more Annual report See our latest 2023 Annual Report on Form 10-K. Learn more The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie’s website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates. For more information Contact us » Subscribe for email alerts Sign up Subscription management AbbVie social media twitter facebook linkedin Instagram youtube We also welcome the opportunity to hear from you in these social channels, but remember we work in a highly-regulated industry with unique legal considerations. Before engaging, please read and adhere to our established community guidelines for each channel. View our social media channel guidelines » AbbVie.com | Site Map | Terms of Use | Privacy Notice | Consumer Health Data Privacy Notice | Cookie Settings | Your Privacy Choices Copyright © 2024 AbbVie Inc. North Chicago, Illinois, U.S.A. Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company. YOU ARE ABOUT TO LEAVE FOR A 3RD PARTY WEBSITE Notice The "Yes" link below will take you out of the AbbVie family of websites. Links which take you out of the AbbVie worldwide websites are not under the control of AbbVie, and AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply endorsement of the linked site by AbbVie. The Internet site that you have requested may not be optimized to your screen size. Do you wish to leave this...